Apr 21 - From Evidence to Action: Scaling Pharmacogenomics in Clinical Practice Key Insights from the 2026 ACMG Annual Clinical Genetics Meeting- R. Rodney Howell Symposium OnDemand-Apr 21 - From Evidence to Action: Scaling Pharmacogenomics in Clinical Practice Key Insights

Video Transcription

Video Summary

The ACMG “Translating Genes into Health” webinar (April 21, 2026) focused on moving pharmacogenomics (PGx) from evidence and guidelines into sustainable, large-scale clinical care. Moderated by Philip Empey, the session highlighted why scale-up is timely: robust datasets and widely used guidance (e.g., CPIC, FDA) show PGx actionability is common; in the NIH All of Us cohort, about one-quarter of participants had an actionable predicted phenotype and prior exposure to a CPIC A/B medication.<br /><br />Panelists summarized practical implementation lessons. Shirin Shaban reviewed clinical PGx test development choices: targeted genotyping vs sequencing, gene/allele selection (CPIC, AMP tiers, population-specific variants), single-gene vs panels, star-allele calling tools, phenotype reporting, preemptive vs reactive testing, and the need for clinician consultation support. She emphasized future readiness for rapid updates, sequencing expansion, AI tools, and functional assays for uncertain variants.<br /><br />Empey addressed education as a major barrier, presenting role-based, competency-driven training models (champions, decision-makers, responders) and the need for self-paced, multidisciplinary programs with reinforcement.<br /><br />Serene Hadar discussed translating CPIC guidance into EHR clinical decision support (CDS), noting Epic Foundation content and the importance of local tailoring and patient education materials so results remain usable across institutions.<br /><br />Mark Dunneberger emphasized ongoing knowledge maintenance, reporting Endeavor Health’s 42,000+ preemptively tested patients and the need for both interruptive and passive CDS plus standardized annual review processes.<br /><br />Deepak Vohra described VA national scale-up (150+ centers; 150,000+ tested), tracking education, testing uptake, alert concordance, and reductions in drug–gene interaction prescribing after implementation.

Asset Subtitle

Not eligible for Educational Credits - post live meeting. Offered as an OnDemand course in the Academy

Keywords

pharmacogenomics

clinical implementation

CPIC guidelines

EHR clinical decision support

preemptive testing

genotyping

sequencing

clinical education

drug-gene interactions

scale-up